{"transactions":[{"id":717677,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-07-02T20:21:20.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":38862,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units (\"RSU\") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027."}],"balance_after":39721,"source":{"system":"sec-edgar","filing":"0001401914-26-000034","document":"wk-form4_1783023676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000034/wk-form4_1783023676.xml","form_type":"4"}},{"id":737698,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:06:33.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001193125-26-271072","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271072/ownership.xml","form_type":"4"}},{"id":741492,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T21:05:28.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":10000,"derivative":{"exercise_price":2.03,"expiration_date":"2036-06-11","underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001205903-26-000005","document":"wk-form4_1781211925.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000120590326000005/wk-form4_1781211925.xml","form_type":"4"}},{"id":759316,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:02:12.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":2567,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001205903-26-000004","document":"wk-form4_1780092129.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120590326000004/wk-form4_1780092129.xml","form_type":"4"}},{"id":768857,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-21T23:24:01.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":3318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3318},"source":{"system":"sec-edgar","filing":"0001205903-26-000002","document":"wk-form4_1779405838.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120590326000002/wk-form4_1779405838.xml","form_type":"4"}},{"id":768856,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T23:24:01.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":true,"shares":3318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"43,678 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power."}],"balance_after":43678,"source":{"system":"sec-edgar","filing":"0001205903-26-000002","document":"wk-form4_1779405838.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120590326000002/wk-form4_1779405838.xml","form_type":"4"}},{"id":789836,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-06T20:00:22.000Z","date":"2026-05-05","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vested and became exercisable on the date of the 2017 Annual Meeting of Stockholders."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2026-05-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-208891","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526208891/ownership.xml","form_type":"4"}},{"id":789835,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T20:00:22.000Z","date":"2026-05-05","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":1.69,"value":42250.0,"ownership":{"direct":true},"balance_after":36331,"source":{"system":"sec-edgar","filing":"0001193125-26-208891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526208891/ownership.xml","form_type":"4"}},{"id":1006210,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-11-06T22:25:32.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026."}],"balance_after":0,"derivative":{"exercise_price":47.89,"expiration_date":"2026-05-20","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001205903-25-000005","document":"wk-form4_1762467929.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120590325000005/wk-form4_1762467929.xml","form_type":"4"}},{"id":1006209,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-06T22:25:32.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":18000,"price":151.8161,"value":2732689.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2025. Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $153.01. The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"40,360 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power."}],"balance_after":40360,"source":{"system":"sec-edgar","filing":"0001205903-25-000005","document":"wk-form4_1762467929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120590325000005/wk-form4_1762467929.xml","form_type":"4"}},{"id":1006208,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-06T22:25:32.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":true,"shares":18000,"price":47.89,"value":862020.0,"ownership":{"direct":true},"balance_after":58360,"source":{"system":"sec-edgar","filing":"0001205903-25-000005","document":"wk-form4_1762467929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120590325000005/wk-form4_1762467929.xml","form_type":"4"}},{"id":1089229,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-10T20:05:59.000Z","date":"2025-07-09","kind":"grant","planned":false,"acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":4500,"derivative":{"exercise_price":2.44,"expiration_date":"2035-07-09","underlying":"Common stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001401914-25-000040","document":"wk-form4_1752177952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191425000040/wk-form4_1752177952.xml","form_type":"4"}},{"id":1100051,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1100050,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1100049,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.36,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1100048,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.45,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1100047,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.7,"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1100046,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":9.9,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1100045,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2325,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":8.8,"underlying":"Common Stock","underlying_shares":2325},"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1100044,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4650,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":6.4,"underlying":"Common Stock","underlying_shares":4650},"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1100043,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":57292,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive  (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1100042,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T21:12:53.000Z","date":"2025-06-25","kind":"other","planned":false,"acquired":false,"shares":44264,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for the Offer Price."}],"balance_after":57292,"source":{"system":"sec-edgar","filing":"0000950170-25-091036","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025091036/ownership.xml","form_type":"4"}},{"id":1129154,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:09:10.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-079717","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079717/ownership.xml","form_type":"4"}},{"id":1138154,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-22T22:15:50.000Z","date":"2025-05-22","kind":"exercise","planned":false,"acquired":false,"shares":2869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2869},"source":{"system":"sec-edgar","filing":"0000914475-25-000134","document":"wk-form4_1747952144.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000134/wk-form4_1747952144.xml","form_type":"4"}},{"id":1138153,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-22T22:15:50.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":3318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest in full on May 21, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest in full on May 21, 2026."}],"balance_after":3318,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3318},"source":{"system":"sec-edgar","filing":"0000914475-25-000134","document":"wk-form4_1747952144.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000134/wk-form4_1747952144.xml","form_type":"4"}},{"id":1138152,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T22:15:50.000Z","date":"2025-05-22","kind":"exercise","planned":false,"acquired":true,"shares":2869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"40,360 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power."}],"balance_after":40360,"source":{"system":"sec-edgar","filing":"0000914475-25-000134","document":"wk-form4_1747952144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000134/wk-form4_1747952144.xml","form_type":"4"}},{"id":1156595,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-05-07T23:05:35.000Z","date":"2025-05-05","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options were due to expire on May 28, 2025."}],"balance_after":0,"derivative":{"exercise_price":42.76,"expiration_date":"2025-05-28","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000914475-25-000103","document":"wk-form4_1746659129.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000103/wk-form4_1746659129.xml","form_type":"4"}},{"id":1156594,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-07T23:05:35.000Z","date":"2025-05-05","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":110.1984,"value":3305952.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $108.13 to $111.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"37,491 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power."}],"balance_after":37491,"source":{"system":"sec-edgar","filing":"0000914475-25-000103","document":"wk-form4_1746659129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000103/wk-form4_1746659129.xml","form_type":"4"}},{"id":1156593,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-07T23:05:35.000Z","date":"2025-05-05","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":42.76,"value":1282800.0,"ownership":{"direct":true},"balance_after":67491,"source":{"system":"sec-edgar","filing":"0000914475-25-000103","document":"wk-form4_1746659129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000103/wk-form4_1746659129.xml","form_type":"4"}},{"id":1163288,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T20:30:05.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Rastetter Family Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 30, 2025, the Reporting Person was granted 62,500 Restricted Stock Units (the \"Award\").  The Award vests in equal monthly installments over the 12 months from the date of grant."}],"balance_after":101556,"source":{"system":"sec-edgar","filing":"0000950170-25-061111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017025061111/ownership.xml","form_type":"4"}},{"id":1431893,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-16T21:00:51.000Z","date":"2024-08-15","kind":"sale","planned":false,"acquired":false,"shares":14250,"price":146.69,"value":2090332.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person contributed Issuer common stock to an exchange fund for shares of the exchange fund.  The Issuer common stock was valued at $146.69 per share for the purpose of determining the number of shares of the exchange fund issuable to the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"All of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power."}],"balance_after":37491,"source":{"system":"sec-edgar","filing":"0000914475-24-000197","document":"wk-form4_1723842044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000197/wk-form4_1723842044.xml","form_type":"4"}},{"id":1483336,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:35:12.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-071970","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024071970/ownership.xml","form_type":"4"}},{"id":1486568,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T21:15:37.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":40000,"derivative":{"exercise_price":0.43,"expiration_date":"2034-06-05","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-24-023179","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224023179/ownership.xml","form_type":"4"}},{"id":1504417,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-23T22:51:01.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":2869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 22, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 22, 2025."}],"balance_after":2869,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2869},"source":{"system":"sec-edgar","filing":"0000914475-24-000158","document":"wk-form4_1716504649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000158/wk-form4_1716504649.xml","form_type":"4"}},{"id":1506923,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-21T20:24:04.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Rastetter Family Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":60000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-062936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017024062936/ownership.xml","form_type":"4"}},{"id":1510908,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T20:37:56.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Rastetter Family Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of\nStockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the\nCompany's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-061744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000095017024061744/ownership.xml","form_type":"4"}},{"id":1689186,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2024-01-04T23:26:12.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.98,"value":259600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted May 22, 2014 and vested in 12 equal monthly installments beginning June 22, 2014.  These options will expire ten years from the date of grant on May 22, 2024."}],"balance_after":0,"derivative":{"exercise_price":12.98,"expiration_date":"2024-05-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000914475-24-000006","document":"wk-form4_1704410754.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000006/wk-form4_1704410754.xml","form_type":"4"}},{"id":1689185,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T23:26:12.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":11044,"price":131.4675,"value":1451927.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.76 to $133.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"42,785 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power"}],"balance_after":51741,"source":{"system":"sec-edgar","filing":"0000914475-24-000006","document":"wk-form4_1704410754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000006/wk-form4_1704410754.xml","form_type":"4"}},{"id":1689184,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T23:26:12.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":12.98,"value":259600.0,"ownership":{"direct":true},"balance_after":62785,"source":{"system":"sec-edgar","filing":"0000914475-24-000006","document":"wk-form4_1704410754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000006/wk-form4_1704410754.xml","form_type":"4"}},{"id":1808364,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-14T20:31:11.000Z","date":"2023-08-10","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Rastetter Family Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant, subject to the Reporting Person's continuous service."}],"balance_after":15000,"derivative":{"exercise_price":1.36,"expiration_date":"2033-08-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-045639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919123045639/doc4.xml","form_type":"4"}},{"id":1847698,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-22T01:39:48.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":40000,"derivative":{"exercise_price":0.96,"expiration_date":"2033-06-21","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001401914-23-000028","document":"wk-form4_1687397979.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191423000028/wk-form4_1687397979.xml","form_type":"4"}},{"id":1857017,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T20:53:31.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Rastetter Family Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":1.45,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-036777","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919123036777/doc4.xml","form_type":"4"}},{"id":1863775,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-07T20:13:32.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":5.52,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-035062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123035062/doc4.xml","form_type":"4"}},{"id":1885694,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2023-05-19T21:21:41.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":8579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 monthly installments beginning June 17, 2023."}],"balance_after":8579,"derivative":{"exercise_price":95.27,"expiration_date":"2033-05-17","underlying":"Common Stock","underlying_shares":8579},"source":{"system":"sec-edgar","filing":"0001209191-23-031119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123031119/doc4.xml","form_type":"4"}},{"id":1906920,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2023-05-03T21:34:04.000Z","date":"2023-05-01","kind":"exercise","planned":true,"acquired":false,"shares":7625,"price":12.71,"value":96913.75,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted May 23, 2013 and vested in 12 equal monthly installments beginning June 23, 2013."}],"balance_after":0,"derivative":{"exercise_price":12.71,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":7625},"source":{"system":"sec-edgar","filing":"0001209191-23-027095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123027095/doc4.xml","form_type":"4"}},{"id":1906919,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T21:34:04.000Z","date":"2023-05-01","kind":"sale","planned":true,"acquired":false,"shares":4300,"price":101.4268,"value":436135.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on May 19, 2022.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.87 to $101.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"34,022 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power."}],"balance_after":42785,"source":{"system":"sec-edgar","filing":"0001209191-23-027095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123027095/doc4.xml","form_type":"4"}},{"id":1906918,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T21:34:04.000Z","date":"2023-05-01","kind":"exercise","planned":true,"acquired":true,"shares":7625,"price":12.71,"value":96913.75,"ownership":{"direct":true},"balance_after":47085,"source":{"system":"sec-edgar","filing":"0001209191-23-027095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123027095/doc4.xml","form_type":"4"}},{"id":1915857,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2023-04-21T22:58:33.000Z","date":"2023-04-21","kind":"exercise","planned":true,"acquired":false,"shares":10765,"price":12.71,"value":136823.15,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted May 23, 2013 and vested in 12 equal monthly installments beginning June 23, 2013."}],"balance_after":7625,"derivative":{"exercise_price":12.71,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":10765},"source":{"system":"sec-edgar","filing":"0001209191-23-025273","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123025273/doc4.xml","form_type":"4"}},{"id":1915856,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2023-04-21T22:58:33.000Z","date":"2023-04-19","kind":"exercise","planned":true,"acquired":false,"shares":1610,"price":12.71,"value":20463.1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted May 23, 2013 and vested in 12 equal monthly installments beginning June 23, 2013."}],"balance_after":18390,"derivative":{"exercise_price":12.71,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":1610},"source":{"system":"sec-edgar","filing":"0001209191-23-025273","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123025273/doc4.xml","form_type":"4"}},{"id":1915855,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-21T22:58:33.000Z","date":"2023-04-21","kind":"sale","planned":true,"acquired":false,"shares":6034,"price":105.0359,"value":633786.6206,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on May 19, 2022.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"34,022 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power."}],"balance_after":39460,"source":{"system":"sec-edgar","filing":"0001209191-23-025273","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123025273/doc4.xml","form_type":"4"}},{"id":1915854,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-21T22:58:33.000Z","date":"2023-04-21","kind":"exercise","planned":true,"acquired":true,"shares":10765,"price":12.71,"value":136823.15,"ownership":{"direct":true},"balance_after":45494,"source":{"system":"sec-edgar","filing":"0001209191-23-025273","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123025273/doc4.xml","form_type":"4"}},{"id":1915853,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-21T22:58:33.000Z","date":"2023-04-19","kind":"sale","planned":true,"acquired":false,"shares":903,"price":105.004,"value":94818.612,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on May 19, 2022.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34729,"source":{"system":"sec-edgar","filing":"0001209191-23-025273","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123025273/doc4.xml","form_type":"4"}},{"id":1915852,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-21T22:58:33.000Z","date":"2023-04-19","kind":"exercise","planned":true,"acquired":true,"shares":1610,"price":12.71,"value":20463.1,"ownership":{"direct":true},"balance_after":35632,"source":{"system":"sec-edgar","filing":"0001209191-23-025273","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123025273/doc4.xml","form_type":"4"}},{"id":2221928,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:52:30.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":38000,"derivative":{"exercise_price":1.31,"expiration_date":"2032-06-23","underlying":"Common stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001401914-22-000071","document":"wf-form4_165610393127419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191422000071/wf-form4_165610393127419.xml","form_type":"4"}},{"id":2234039,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T20:43:27.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":11893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":11893,"derivative":{"exercise_price":23.48,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":11893},"source":{"system":"sec-edgar","filing":"0001209191-22-036353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919122036353/doc4.xml","form_type":"4"}},{"id":2234038,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-13T20:43:27.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Award of restricted stock units that vest in full on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":11331,"source":{"system":"sec-edgar","filing":"0001209191-22-036353","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919122036353/doc4.xml","form_type":"4"}},{"id":2235642,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:17:37.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Rastetter Family Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":90000,"derivative":{"exercise_price":0.27,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-22-035868","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919122035868/doc4.xml","form_type":"4"}},{"id":2262528,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2022-05-20T20:14:29.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":9724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 monthly installments beginning June 18, 2022."}],"balance_after":9724,"derivative":{"exercise_price":84.95,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":9724},"source":{"system":"sec-edgar","filing":"0001209191-22-030992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122030992/doc4.xml","form_type":"4"}},{"id":2305859,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2022-04-05T22:20:30.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":20000,"price":6.66,"value":133200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted May 23, 2012 and vested in 12 equal monthly installments beginning June 23, 2012."}],"balance_after":0,"derivative":{"exercise_price":6.66,"expiration_date":"2022-05-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-023284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122023284/doc4.xml","form_type":"4"}},{"id":2305858,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T22:20:30.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":10728,"price":94.926,"value":1018366.128,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $93.48 to $95.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34022,"source":{"system":"sec-edgar","filing":"0001209191-22-023284","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122023284/doc4.xml","form_type":"4"}},{"id":2305857,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T22:20:30.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":20000,"price":6.66,"value":133200.0,"ownership":{"direct":true},"balance_after":44750,"source":{"system":"sec-edgar","filing":"0001209191-22-023284","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122023284/doc4.xml","form_type":"4"}},{"id":2655731,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-24T20:35:21.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":30000,"derivative":{"exercise_price":1.46,"expiration_date":"2031-06-24","underlying":"Common stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001401914-21-000090","document":"wf-form4_162456686646072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191421000090/wf-form4_162456686646072.xml","form_type":"4"}},{"id":2667939,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T20:44:53.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":40000,"derivative":{"exercise_price":0.9877,"expiration_date":"2031-06-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-040624","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919121040624/doc4.xml","form_type":"4"}},{"id":2680819,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T21:30:04.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":4334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":4334,"derivative":{"exercise_price":68.94,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":4334},"source":{"system":"sec-edgar","filing":"0000899243-21-022086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000089924321022086/doc4.xml","form_type":"4"}},{"id":2680818,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T21:30:04.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":2681,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Award of restricted stock units that vest in full on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":2681,"source":{"system":"sec-edgar","filing":"0000899243-21-022086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000089924321022086/doc4.xml","form_type":"4"}},{"id":2703968,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2021-05-20T20:11:48.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":8833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 equal monthly installments beginning June 19, 2021."}],"balance_after":8833,"derivative":{"exercise_price":92.35,"exercise_date":"2021-06-19","expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":8833},"source":{"system":"sec-edgar","filing":"0001209191-21-034392","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121034392/doc4.xml","form_type":"4"}},{"id":2761026,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T20:24:09.000Z","date":"2020-03-30","kind":"gift","acquired":true,"shares":28461,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Rastetter Family Trust, dated 09/02/10"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned of record by The Investment 2002 Trust, dated November 11, 2002 for which William H. Rastetter is the sole trustee and owner."}],"balance_after":146821,"source":{"system":"sec-edgar","filing":"0000899243-21-014588","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000089924321014588/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-31"}},{"id":2761025,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T20:24:09.000Z","date":"2020-03-30","kind":"gift","acquired":false,"shares":28461,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014588","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000089924321014588/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-31"}},{"id":3098395,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-27T00:56:12.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":22500,"derivative":{"exercise_price":1.03,"expiration_date":"2030-06-25","underlying":"Common stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001401914-20-000096","document":"wf-form4_159321935213925.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191420000096/wf-form4_159321935213925.xml","form_type":"4"}},{"id":3104086,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T20:42:03.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":23250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"THE RASTETTER FAMILY TRUST DTD 9-2-2010"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":23250,"derivative":{"exercise_price":0.88,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":23250},"source":{"system":"sec-edgar","filing":"0001209191-20-037957","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919120037957/doc4.xml","form_type":"4"}},{"id":3139706,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2020-05-21T22:42:11.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":6018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 equal monthly installments beginning June 19, 2020."}],"balance_after":6018,"derivative":{"exercise_price":119.93,"exercise_date":"2020-06-19","expiration_date":"2030-05-19","underlying":"Common Stock","underlying_shares":6018},"source":{"system":"sec-edgar","filing":"0001209191-20-031463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120031463/doc4.xml","form_type":"4"}},{"id":3161027,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-05T20:19:44.000Z","date":"2020-05-01","kind":"grant","acquired":true,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 1, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors."}],"balance_after":16000,"derivative":{"exercise_price":26.59,"expiration_date":"2030-05-01","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-20-027107","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919120027107/doc4.xml","form_type":"4"}},{"id":3190788,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-03-31T20:01:27.000Z","date":"2020-03-30","kind":"exercise","acquired":false,"shares":28461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":1.37,"expiration_date":"2023-02-05","underlying":"Common Stock","underlying_shares":28461},"source":{"system":"sec-edgar","filing":"0001209191-20-021788","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919120021788/doc4.xml","form_type":"4"}},{"id":3190787,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2020-03-31T20:01:27.000Z","date":"2020-03-30","kind":"exercise","acquired":true,"shares":28461,"price":1.37,"value":38991.57,"ownership":{"direct":true},"balance_after":28461,"source":{"system":"sec-edgar","filing":"0001209191-20-021788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919120021788/doc4.xml","form_type":"4"}},{"id":3290993,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A-2 Convertible Preferred Stock","published_at":"2020-02-04T22:05:44.000Z","date":"2020-02-03","kind":"exercise","acquired":false,"shares":22594,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Rastetter Family Trust dtd 9-2-2010"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class A-2 Convertible Preferred have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":225940},"source":{"system":"sec-edgar","filing":"0001209191-20-006435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919120006435/doc4.xml","form_type":"4"}},{"id":3290992,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-04T22:05:44.000Z","date":"2020-02-03","kind":"exercise","acquired":true,"shares":225940,"ownership":{"direct":false,"nature":"The Rastetter Family Trust dtd 9-2-2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Class A-2 Convertible Preferred have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":390584,"source":{"system":"sec-edgar","filing":"0001209191-20-006435","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919120006435/doc4.xml","form_type":"4"}},{"id":3331080,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-12-26T13:52:37.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":225940,"price":0.125,"value":28242.5,"ownership":{"direct":false,"nature":"THE RASTETTER FAMILY TRUST DTD 9-2-2010"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":225940,"derivative":{"exercise_price":0.666,"exercise_date":"2019-12-24","expiration_date":"2024-12-24","underlying":"Common Stock","underlying_shares":225940},"source":{"system":"sec-edgar","filing":"0001209191-19-061856","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919119061856/doc4.xml","form_type":"4"}},{"id":3331079,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A-2 Convertible Preferred Stock","published_at":"2019-12-26T13:52:37.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":22594,"price":6.66,"value":150476.04,"ownership":{"direct":false,"nature":"THE RASTETTER FAMILY TRUST DTD 9-2-2010"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":22594,"derivative":{"underlying":"Common Stock","underlying_shares":225940},"source":{"system":"sec-edgar","filing":"0001209191-19-061856","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919119061856/doc4.xml","form_type":"4"}},{"id":3393536,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-15T20:46:13.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":46500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"THE RASTETTER FAMILY TRUST DTD 9-2-2010"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":46500,"derivative":{"exercise_price":0.64,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":46500},"source":{"system":"sec-edgar","filing":"0001209191-19-053168","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919119053168/doc4.xml","form_type":"4"}},{"id":3489412,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T18:33:30.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":22500,"derivative":{"exercise_price":0.9,"expiration_date":"2029-06-13","underlying":"Common stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001401914-19-000064","document":"wf-form4_156053719512628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191419000064/wf-form4_156053719512628.xml","form_type":"4"}},{"id":3514015,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2019-05-23T21:53:16.000Z","date":"2019-05-22","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 equal monthly installments beginning June 22, 2019."}],"balance_after":13000,"derivative":{"exercise_price":79.79,"exercise_date":"2019-06-22","expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001209191-19-032407","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119032407/doc4.xml","form_type":"4"}},{"id":3516618,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-05-21T20:45:05.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":92889,"price":0.125,"value":11611.125,"ownership":{"direct":false,"nature":"The Rastetter Family Trust DTD 9-2-2010"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":92889,"derivative":{"exercise_price":1.08,"exercise_date":"2019-05-07","expiration_date":"2024-05-07","underlying":"Common Stock","underlying_shares":92889},"source":{"system":"sec-edgar","filing":"0001209191-19-031766","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919119031766/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-08"}},{"id":3516617,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-21T20:45:05.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":92889,"price":1.08,"value":100320.12,"ownership":{"direct":false,"nature":"The Rastetter Family Trust DTD 9-2-2010"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":154223,"source":{"system":"sec-edgar","filing":"0001209191-19-031766","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919119031766/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-08"}},{"id":3534940,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-05-08T21:14:20.000Z","date":"2019-05-07","kind":"purchase","acquired":true,"shares":92889,"price":0.125,"value":11611.125,"ownership":{"direct":false,"nature":"THE RASTETTER FAMILY TRUST DTD 09-02-2010"},"balance_after":92889,"derivative":{"exercise_price":1.08,"exercise_date":"2019-05-07","expiration_date":"2024-05-07","underlying":"Common Stock","underlying_shares":92889},"source":{"system":"sec-edgar","filing":"0001209191-19-028277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919119028277/doc4.xml","form_type":"4"}},{"id":3534939,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-08T21:14:20.000Z","date":"2019-05-07","kind":"purchase","acquired":true,"shares":92889,"price":1.08,"value":100320.12,"ownership":{"direct":false,"nature":"THE RASTETTER FAMILY TRUST DTD 9-2-2010"},"balance_after":154223,"source":{"system":"sec-edgar","filing":"0001209191-19-028277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919119028277/doc4.xml","form_type":"4"}},{"id":3536426,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-07T20:07:11.000Z","date":"2019-05-03","kind":"grant","acquired":true,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 3, 2020 or (ii) the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors."}],"balance_after":16000,"derivative":{"exercise_price":17.15,"expiration_date":"2029-05-03","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-19-027952","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919119027952/doc4.xml","form_type":"4"}},{"id":3766483,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T22:33:29.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":4583,"ownership":{"direct":false,"nature":"William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The cancelled option vested in twelve equally monthly installments, such that the option would have been fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occured first."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":8.76,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":4583},"source":{"system":"sec-edgar","filing":"0001209191-18-058344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118058344/doc4.xml","form_type":"4"}},{"id":3766482,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T22:33:29.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":6250,"ownership":{"direct":false,"nature":"William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":8.52,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001209191-18-058344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118058344/doc4.xml","form_type":"4"}},{"id":3766481,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T22:33:29.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":2500,"ownership":{"direct":false,"nature":"William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":17.4,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-18-058344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118058344/doc4.xml","form_type":"4"}},{"id":3766480,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T22:33:29.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":3051,"ownership":{"direct":false,"nature":"William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":74.4,"expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":3051},"source":{"system":"sec-edgar","filing":"0001209191-18-058344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118058344/doc4.xml","form_type":"4"}},{"id":3766479,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T22:33:29.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":false,"nature":"William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":120.24,"expiration_date":"2025-06-08","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-058344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118058344/doc4.xml","form_type":"4"}},{"id":3766478,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T22:33:29.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":false,"nature":"William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":74.64,"expiration_date":"2024-05-21","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-058344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118058344/doc4.xml","form_type":"4"}},{"id":3766477,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T22:33:29.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":false,"nature":"William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":111.84,"expiration_date":"2023-06-09","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-058344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118058344/doc4.xml","form_type":"4"}},{"id":3766476,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T22:33:29.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":2500,"ownership":{"direct":false,"nature":"William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":92.04,"expiration_date":"2023-03-31","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-18-058344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118058344/doc4.xml","form_type":"4"}},{"id":3766475,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-13T22:33:29.000Z","date":"2018-11-12","kind":"grant","acquired":true,"shares":23258,"ownership":{"direct":false,"nature":"William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I.  The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":79672,"source":{"system":"sec-edgar","filing":"0001209191-18-058344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118058344/doc4.xml","form_type":"4"}},{"id":3869208,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-11T21:45:31.000Z","date":"2018-07-10","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 1/3rd of the shares subject to this option on each of July 10, 2019, 2020 and 2021, subject to the reporting person's continued service to the issuer, and will become exercisable in full upon a change of control of the issuer."}],"balance_after":45000,"derivative":{"exercise_price":1.35,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-18-042385","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000120919118042385/doc4.xml","form_type":"4"}},{"id":3904813,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T20:30:41.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Rastetter Family Trust dated 9-2-2010"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first."}],"balance_after":55000,"derivative":{"exercise_price":0.73,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-18-035702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118035702/doc4.xml","form_type":"4"}},{"id":3917721,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2018-05-26T00:03:14.000Z","date":"2018-05-24","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 equal monthly installments beginning June 24, 2018."}],"balance_after":15000,"derivative":{"exercise_price":94.64,"exercise_date":"2018-06-24","expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-033635","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118033635/doc4.xml","form_type":"4"}},{"id":3923726,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-21T20:42:34.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Rastetter Family Trust dated 9-2-2010"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first."}],"balance_after":75000,"derivative":{"exercise_price":0.71,"expiration_date":"2028-05-17","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-031895","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205903/000120919118031895/doc4.xml","form_type":"4"}},{"id":3945503,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-04T20:20:58.000Z","date":"2018-05-02","kind":"grant","acquired":true,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 2, 2019 or (ii) the date of the 2019 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors."}],"balance_after":16000,"derivative":{"exercise_price":9.78,"expiration_date":"2028-05-02","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-18-028109","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919118028109/doc4.xml","form_type":"4"}}],"next_cursor":"2018-05-04T20:20:58.000000Z,3945503"}